NXTC Insider Grant: 18.7K Options to Director Houston at $0.47

Rhea-AI Filing Summary

NextCure, Inc. (NXTC) – Form 4 Insider Filing

Director John G. Houston reported the grant of a stock option for 18,700 shares of common stock on 06/20/2025 at an exercise price of $0.47 per share. The option vests in full on the earlier of 06/20/2026 or the 2026 Annual Meeting of Stockholders and expires on 06/19/2035. After the grant, Houston beneficially owns 18,700 derivative securities; no common shares were purchased or sold.

This appears to be a routine equity incentive award for a non-employee director. The grant aligns the director’s interests with shareholders but represents a modest potential dilution and involves no immediate cash expenditure by the insider.

Insights

Financial Analyst

TL;DR: Routine option grant; minimal dilution, neutral market impact.

The filing discloses a single option award to Director Houston. At 18,700 shares and a $0.47 strike, the grant value is small relative to NextCure’s share count and thus immaterial to valuation. No common stock was traded, so supply–demand dynamics remain unchanged. Investors should view this as standard board compensation rather than a signal of management sentiment or upcoming corporate actions.

Corporate Governance Specialist

TL;DR: Positive governance signal via equity-based alignment.

Granting options to non-employee directors ties compensation directly to shareholder returns, reinforcing alignment. The one-year cliff vesting ensures ongoing board engagement through at least the 2026 AGM. While the grant is small, it follows best-practice governance principles and imposes no immediate cash burden on the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Houston John G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,700	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,700 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Houston John G

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.47	06/20/2025		A		18,700		(1)	06/19/2035	Common Stock	18,700	$0	18,700	D

Explanation of Responses:

1. The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

	/s/ Steven P. Cobourn, as attorney-in-fact for John G. Houston	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity was reported in NextCure's (NXTC) latest Form 4?

Director John G. Houston received an option to purchase 18,700 shares at $0.47 per share.

When do the newly granted NXTC options vest and expire?

They vest on the earlier of 06/20/2026 or the 2026 AGM and expire on 06/19/2035.

Did the director buy or sell any common stock in this filing?

No common shares were bought or sold; only a derivative (option) grant was reported.

How many derivative securities does John G. Houston hold after the transaction?

He beneficially owns 18,700 stock options following the reported grant.

What is the exercise price of the options granted to the NXTC director?

The exercise price is $0.47 per share.